Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Temazepam is a benzodiazepine used primarily for the short-term treatment of insomnia, including difficulty falling asleep and staying asleep. It acts by enhancing the effect of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, at the GABA-A receptor in the brain. This results in sedative, anxiolytic, muscle relaxant, and anticonvulsant effects. Temazepam is typically administered orally as a capsule and is intended for use over brief periods (generally 7–10 days) due to risks of dependence and tolerance. It may also be used as premedication before surgical or dental procedures to induce relaxation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on temazepam.